A Randomised, 3-Period, 3-Treatment, Single-dose, Open-label, Single-center, Crossover Study to Assess the Fed-state Bioequivalence of a Triple Fixed-Combination Drug Product of 2.5 mg Saxagliptin / 5 mg Dapagliflozin / 1000 mg Metformin XR and 5 mg Saxagliptin / 10 mg Dapagliflozin / 1000 mg Metformin XR Relative to Individual Components (Onglyza and XIGDUO XR) Co-administered to Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Dapagliflozin/metformin/saxagliptin (Primary) ; Dapagliflozin/metformin; Saxagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 11 Aug 2017 Status changed from active, no longer recruiting to completed.
- 02 Aug 2017 Status changed from recruiting to active, no longer recruiting.